首页> 美国卫生研究院文献>AIDS Research and Human Retroviruses >Evaluation of Heterologous Vaginal SHIV SF162p4 Infection Following Vaccination with a Polyvalent Clade B Virus-Like Particle Vaccine
【2h】

Evaluation of Heterologous Vaginal SHIV SF162p4 Infection Following Vaccination with a Polyvalent Clade B Virus-Like Particle Vaccine

机译:多价进化枝B病毒样颗粒疫苗接种后异种阴道SHIV SF162p4感染的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The vast diversity of HIV-1 infections has greatly impeded the development of a successful HIV-1/AIDS vaccine. Previous vaccine work has demonstrated limited levels of protection against SHIV/SIV infection, but protection was observed only when the challenge virus was directly matched to the vaccine strain. As it is likely impossible to directly match the vaccine strain to all infecting strains in nature, it is necessary to develop an HIV-1 vaccine that can protect against a heterologous viral challenge. In this study we investigated the ability of polyvalent and consensus vaccines to protect against a heterologous clade B challenge. Rhesus macaques were vaccinated with ConB or PolyB virus-like particle vaccines. All vaccines were highly immunogenic with high titers of antibody found in all vaccinated groups against SIV Gag. Antibody responses were also observed against a diverse panel of clade B envelopes. Following vaccination nonhuman primates (NHPs) were challenged via the vaginal route with SHIVSF162p4. The PolyB vaccine induced a 66.7% reduction in the rate of infection as well as causing a two log reduction in viral burden if infection was not blocked. ConB vaccination had no effect on either the infection rate or viral burden. These results indicate that a polyvalent clade-matched vaccine is better able to protect against a heterologous challenge as compared to a consensus vaccine.
机译:HIV-1感染的多样性极大地阻碍了成功的HIV-1 / AIDS疫苗的开发。先前的疫苗工作证明了针对SHIV / SIV感染的保护作用水平有限,但是只有在将攻击病毒直接与疫苗株匹配时才能观察到保护作用。由于不可能将疫苗株与自然界中所有感染株直接匹配,因此有必要开发一种可以防御异源病毒攻击的HIV-1疫苗。在这项研究中,我们调查了多价疫苗和共识疫苗针对异源进化枝B攻击的防御能力。恒河猴猕猴接种了ConB或PolyB病毒样颗粒疫苗。所有疫苗均具有高度免疫原性,并且在所有接种疫苗的组中均发现针对SIV Gag的高滴度抗体。还观察到针对各种各样的进化枝B包膜的抗体应答。接种疫苗后,非人类灵长类动物(NHP)通过阴道途径用SHIVSF162p4攻击。如果不阻止感染,PolyB疫苗可导致感染率降低66.7%,并减少两倍的病毒载量。 ConB疫苗接种对感染率或病毒负担均无影响。这些结果表明,与共有疫苗相比,多价进化枝匹配的疫苗能够更好地防御异源攻击。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号